Protagonist Therapeutics Inc Earnings

Protagonist Therapeutics Inc’s revenue jumped 33.09% since last year same period to $5.55Mn in the Q2 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -80.42% fall in its revenue since last 3-months.

Protagonist Therapeutics Inc’s net profit fell -13.57% since last year same period to $-34.77Mn in the Q2 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -198.34% fall in its net profits since last 3-months.

Protagonist Therapeutics Inc’s net profit margin jumped 14.67% since last year same period to -626.96% in the Q2 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -1423.47% fall in its net profit margins since last 3-months.

Protagonist Therapeutics Inc’s price-to-earnings ratio after this Q2 2025 earnings stands at 79.97.

Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.62 - a -6.9% fall from last quarter’s estimates.

Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.62.

Protagonist Therapeutics Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Protagonist Therapeutics Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.